

TALENT POOL

EXECUTIVE APPOINTMENTS
AND PROMOTIONS IN THE
HEALTHCARE INDUSTRYPharmaceutical **POOL**Dr. Peter **CARBERRY**Dan **DUNHAM**Dr. Betsy **GAROFALO**Walt **JOHNSTON**Astellas Pharma's U.S. Subsidiaries
Name VPs

Tokyo-based Astellas Pharma Inc. has announced a number of new executives at its two U.S.-based subsidiaries.

Astellas Pharma Global Development (APGD) has hired Peter Carberry, M.D., as senior VP and head of global development operations.

In this role, Dr. Carberry is responsible for enhancing the effectiveness and efficiency of the integrated global operational platform, including the data sciences and clinical operations organizations.

Dr. Carberry was most recently the VP of clinical operations, development planning and performance analysis, and the office of international development at Genentech.

He earned an MBA from Western Michigan University and an M.D. from the University of Nairobi, and completed a postdoctoral fellowship in clinical pharmacology at the University of Texas.



Astellas Pharma US has named Dan Dunham VP of compliance. Before joining Astellas, Mr. Dunham previously held legal positions at Pfizer, Pharmacia, and Warner-Lambert.

He holds a law degree from Columbia University School of Law.

At APGD, Betsy Garofalo, M.D., has been



appointed the global therapy area leader for CNS. A pediatric neurologist and epileptologist, Dr. Garofalo has more than 17 years of drug development experience.

In 2007, she formed the Michigan Technology and Research Institute, where she provided consulting services to the pharmaceutical industry.

In addition to her work at APGD, Dr. Garofalo is an adjunct associate professor of pediatrics at the University of Michigan.

She received her medical training and completed a pediatric residency at the Indiana University School of Medicine, followed by a fellowship in neurology/pediatric neurology and a fellowship in epilepsy at the University of Michigan.



Walt Johnston has joined Astellas Pharma US as VP of marketing. Mr. Johnston most recently served as national sales director, Vista Rx, for Pfizer.

He received an MBA from Boston College.

Dr. Freda **LEWIS-HALL**

Pfizer Hires Medical Chief

Pfizer has named Freda Lewis-Hall, M.D., chief medical officer and senior VP. In this role, Dr. Lewis-Hall is Pfizer's senior physician responsible for enterprisewide medical, patient safety, regulatory affairs, and quality assurance, as well as outreach to doctors and other medical professionals.

Dr. Lewis-Hall joins Pfizer from Vertex Pharmaceuticals, where she was executive VP, medicines development, and chief medical officer.

She received an M.D. from Howard University Hospital and College of Medicine and is a fellow of the American Academy of Psychiatry.

Dr. Peter **MUELLER**

Vertex Expands VP's Role

Vertex Pharmaceuticals has appointed Peter Mueller, Ph.D., to the expanded role of executive VP, global research and development and chief scientific officer. Dr. Mueller was previously executive VP, drug innovation and realization, and chief scientific officer.

In this new role, Dr. Mueller is responsible for all Vertex global research and development, including clinical and non-clinical development, clinical operations, and medical and regulatory affairs.

In addition to these new responsibilities, Dr. Mueller retains his current leadership of drug discovery and research, as well as pharmaceutical development, quality assurance and control, and pharmaceutical operations.

Dr. Mueller received a Ph.D. in chemistry from the Albert Einstein University of Ulm, Germany, where he also holds a professorship in theoretic organic chemistry. He completed fellowships in quantum pharmacology at Oxford University and in biophysics at Rochester University.

Dr. Azmi **NABULSI**Takeda Selects President of Global R&D
Center

Azmi Nabulsi, M.D., M.P.H., has joined Takeda Global Research & Development Center, U.S., as president.

Dr. Nabulsi is responsible for directing all aspects of Takeda's drug development activities in the United States, including the identification of new product candidates, execution of clinical trial programs, and support for innovative life-cycle management approaches for Takeda's marketed products.

Dr. Nabulsi has been with Takeda since 2004, most recently as general manager for Takeda's strategic development department based in Osaka, Japan.

He received a medical degree from Ain-Shams University in Cairo and a master's of public health from the University of Minnesota.

Bart **PETERSON**Former Indianapolis Mayor Joins Lilly
Executive Team

Former Indianapolis Mayor Bart Peterson



has joined Eli Lilly as senior VP of corporate affairs and communications.

Mr. Peterson's responsibilities include leading the company's interactions with the public health sector and other payers worldwide and Lilly's effort to support reform of the U.S. healthcare system.

After serving as mayor of Indianapolis from 1999 to 2007, Mr. Peterson served a semester as resident fellow in the Kennedy School of Government at Harvard University.

In addition, Mr. Peterson was managing partner of an urban redevelopment fund for Strategic Capital Partners, and he served a one-year appointment as an urban fellow to Living Cities.

He received a J.D. with honors from University of Michigan Law School.

Biotechnology POOL

Marty **DUVALL**

Dr. Edward **GEEHR**

Leon (Lonnie) **MOULDER Jr.**

Dr. Patrick **SOON-SHIONG**

Bruce **WENDEL**

Global biotechnology company Abraxis BioScience has announced a number of leadership changes at both Abraxis BioScience and Abraxis Health, a spinoff focused on biomarkers and personalized medicine.

Abraxis BioScience has appointed Marty Duvall as senior VP, global marketing and international commercial operations. In this role, Mr. Duvall and his team are responsible for expanding the Abraxane brand franchise, both geographically and by launching new indications.

Mr. Duvall most recently served as chief business officer of Morphotek, a subsidiary of Eisai Corporation of North America.

He earned a master's degree in chemistry from The Johns Hopkins University and an MBA from the University of Kansas.

Edward Geehr, M.D., has been named president and chief operating officer of Abraxis Health. Dr. Geehr has served as executive VP of operations for Abraxis BioScience since October 2008.

Leon (Lonnie) Moulder Jr., has been appointed vice chairman, president, and CEO of Abraxis BioScience.

Mr. Moulder most recently served as vice chairman of Eisai Corporation of North America following Eisai's acquisition of MGI Pharma, where he served as president and CEO. He received an MBA from the University of Chicago.

Patrick Soon-Shiong, M.D., former chairman and CEO of Abraxis BioScience, has assumed the role of executive chairman and CEO of Abraxis Health.

Also at Abraxis Health, Bruce Wendel has been named vice chairman and executive VP, global business development.

Mr. Wendel was previously executive VP of corporate development at Abraxis BioScience, a position he has held since May 2006. He holds a J.D. from Georgetown University Law School.

Peter **LANKAU**

Former Endo Chief Joins Logical Therapeutics



Logical Therapeutics, a biotechnology company developing products that treat diseases associated with inflammation, has named Peter Lankau CEO.

Mr. Lankau joins Logical Therapeutics from Endo Pharmaceuticals, where he was president and CEO.

Previously, Mr. Lankau was with Alpharma, and he held various management positions at Rhone-Poulenc Rorer.

Dr. Renee **TANNENBAUM**

Elan Names Chief Commercial Officer



Renee Tannenbaum, Pharm.D., has joined Elan as executive VP and chief commercial officer.

Dr. Tannenbaum's responsibilities in this role include ensuring that Elan delivers on the revenue expectations for its marketed products; preparing for the commercialization of the company's pipeline, including its Alzheimer's portfolio; and strengthening the company's overall commercial capabilities and commitment to strong performance.

Dr. Tannenbaum comes to Elan with more than 25 years of global pharmaceutical experience.

She most recently was head of global commercial operations for Novartis Pharma.

She is also an adjunct clinical assistant professor at Philadelphia College of Pharmacy & Sciences.

Biopharmaceutical POOL

Dr. Luiz **BELARDINELLI**

Dr. Norbert

BISCHOFBERGER

Gilead Makes Changes to R&D Group

Gilead Sciences has announced some changes to the company's cardiovascular research and development organization as part of its ongoing integration of CV Therapeutics.

Luiz Belardinelli, M.D., senior VP, cardiovascular therapeutics, is now serving as therapeutic area head for cardiovascular therapeutics in the wake of the transition of Louis Lange, M.D., Ph.D., to a part-time role with Gilead from his previous position as executive VP, cardiovascular therapeutics.

With this transition, Gilead's cardiovascular research and development organization now reports to Norbert Bischofberger, Ph.D., executive VP, research and development and chief scientific officer.

Ron **BENTSUR**

Former CFO Returns to Keryx as CEO

Ron Bentsur has returned to Keryx Biopharmaceuticals as CEO. Keryx is a biopharmaceutical company focused on the acquisition, development, and commercialization of products to treat life-threatening diseases, including renal disease and cancer.

Mr. Bentsur was most recently CEO of XTL Biopharmaceuticals, and before that he served as chief financial officer of Keryx. He earned an MBA magna cum laude from New York University's Stern Graduate School of Business.

Jay **HAGAN**

Dr. Michael **SCAIFE**

Orexigen Adds VPs

Orexigen Therapeutics, a biopharmaceutical company focused on the treatment of obesity, has added two executives to its management team.

Jay Hagan has joined Orexigen as senior VP of corporate development and strategy.

In this role, Mr. Hagan is focusing on part-

TALENT pool

nership opportunities and commercialization strategy for lead products Contrave, which is on track for an NDA submission to the FDA in the first half of 2010; and Empatic, which is in the later stages of Phase II clinical development.

Orexigen also has named Michael Scaife, Ph.D., senior VP of regulatory affairs and product development, Contrave program.

Dr. Scaife most recently served as principal of MChS Consultancy.

He received a Ph.D. in toxicology from Leicester School of Pharmacy in the United Kingdom.

Matthias JAFFE

Zafgen Names Business Development VP

Zafgen, a private venture-backed biopharmaceutical company focused on developing novel obesity therapeutics, has appointed Matthias Jaffe to chief financial officer and VP of business development.

Mr. Jaffe has more than 10 years of experience in corporate finance and strategic management, most recently serving as chief financial officer of Alantos Pharmaceuticals.

He received an M.S. in molecular biology from the Massachusetts Institute of Technology and an MBA from INSEAD in Fontainebleau, France.

Dr. Stephen KELSEY

Hassan MOVAHHED

Geron Expands Oncology Team



Geron has announced two additions to its oncology management team. Stephen Kelsey, M.D., F.R.C.P., F.R.C.Path., has joined Geron as executive VP and chief medical officer, oncology, with responsibility for managing the operational and strategic activities of the company's oncology programs.

Dr. Kelsey was most recently VP, clinical hematology/oncology, for Genentech. He received an M.D., an F.R.C.P., and an F.R.C.Path. from the University of Birmingham in the United Kingdom.



Hassan Movahhed has been appointed VP of clinical operations, oncology. He is responsible for all oncology clinical operations.

Mr. Movahhed was previously VP and head, global clinical operations, at Elan Biopharmaceuticals.

Clare KENNEDY

Pfizer Veteran Joins
PTC Therapeutics

PTC Therapeutics has named Clare Kennedy VP of commercial operations, with responsibility for the company's patient services and distribution functions focusing on product access and reimbursement. PTC is a biopharmaceutical company focused on the discovery, development, and commercialization of orally administered, proprietary, small-molecule drugs that target post-transcriptional control of RNA processes.

Ms. Kennedy joins PTC after 16 years at Pfizer, most recently as VP of account planning. A registered nurse, she received an M.S. in health management from the American University School of Business and College of Arts and Sciences.

Dr. Joel MARTIN

Altair Appoints CEO



Altair Therapeutics, a privately held biopharmaceutical company developing novel therapeutics for respiratory diseases, has named Joel Martin, Ph.D., president and CEO. Dr. Martin succeeds Paul

Brennan, who remains with Altair in a business development capacity.

Most recently, Dr. Martin served as partner at Forward Ventures.

Specialty POOL

Maureen LISTER

Dr. Steve PERRIN

Leadership Shifts at ALS Therapy
Development Institute

The ALS Therapy Development Institute (ALS TDI) has announced the appointment of Maureen Lister as president and Steve Perrin, Ph.D., as CEO following the passing in February of former President Sean Scott due to complications from amyotrophic lateral sclerosis (ALS), also known as Lou Gehrig's disease.

Ms. Lister remains chief operating officer and chief financial officer of ALS TDI, and Dr. Perrin retains his role as ALS TDI's chief scientific officer.

Ms. Lister joined ALS TDI in 2007 as chief

financial officer and was named chief operating officer at the end of 2008.

Dr. Perrin has served as chief scientific officer of ALS TDI since 2007. In this expanded role as CEO, Dr. Perrin is responsible for ensuring the Institute continues to advance its mission.

The Institute is a nonprofit biotechnology company that aims to discover and develop effective therapeutics for ALS.

Fred NICKLAS

Biovail Appoints VP of
BTA Pharmaceuticals Unit

Fred Nicklas has joined Canadian specialty pharmaceutical company Biovail as VP, U.S. commercial operations, of the company's U.S. subsidiary, BTA Pharmaceuticals. In this role, Mr. Nicklas is responsible for overseeing sales, marketing, and managed care efforts for BTA's products.

Mr. Nicklas has 20 years of experience in marketing and sales, largely in areas of specialty central nervous system (CNS) disorders. Before joining Biovail, he served as senior director, epilepsy marketing, at Valeant Pharmaceuticals.

Deebie SYMMES

Napo Appoints Business Development VP



Napo Pharmaceuticals, which focuses on the development and commercialization of proprietary pharmaceuticals for the global marketplace in collaboration with local partners, has appointed

Deebie Symmes VP, business development. In this role, Ms. Symmes is responsible for maximizing the value of Napo's pipeline through partnering arrangements.

Ms. Symmes has nearly two decades of business development experience with pharmaceutical companies such as Chiron, IntraBiotics Pharmaceuticals, Tularik, and ARYx Therapeutics.

Drug-Delivery POOL

Brian MEADOWS

Hospira Names Supply Chain VP

Hospira, a global specialty pharmaceutical

and medication delivery company, has appointed Brian Meadows corporate VP, supply chain. Mr. Meadows is responsible for enterprisewide supply-chain operations, as well as leading the procurement effort within Project Fuel, Hospira's multi-phased initiative designed to identify resources across the organization to reduce complexity, improve efficiencies, and optimize financial performance.

Mr. Meadows was previously senior VP of supply chain management at Sprint Nextel. He received a master of business management from the Kellogg School of Management at Northwestern University.

Device/Diagnostic POOL

Dr. H. Robert SUPERKO

Celera Names Medical Affairs Chief

Celera, a healthcare business delivering personalized disease management through a combination of products and services, has named H. Robert Superko, M.D., VP, chief of medical affairs. In this newly created role, Dr. Superko provides medical leadership for Celera's cardiovascular products and services through oversight of education programs and participation in relevant medical associations, professional societies, and groups responsible for the establishment of guidelines regarding the adoption of new diagnostics.

A founder of Celera subsidiary Berkeley HeartLab, Dr. Superko is a clinical professor in the College of Pharmacy and Health Sciences at Mercer University. He also is a fellow of the American College of Cardiology, the American Heart Association, the American College of Sports Medicine, and the American Association of Cardiovascular and Pulmonary Rehabilitation, and is currently the executive director at the Center for Genomics and Human Health at St. Joseph's Translational Research Institute. He earned a doctor of medicine from the State University of New York, Stony Brook.

Generic POOL

Andrew CUNEO

Mylan Names Business Development VP

Global generic pharmaceutical company

Mylan has appointed former Merrill Lynch investment banker Andrew Cuneo as VP of global business development

He has responsibility for coordinating Mylan's global business development and strategic efforts in close alignment with the company's executive leadership team.

While at Merrill Lynch, Mr. Cuneo worked on strategic advisory and capital markets transactions, primarily in the healthcare sector.

Mr. Cuneo most recently was a director in Merrill Lynch's global healthcare investment banking group.

Emerging POOL

Katrine BOSLEY

Avila Therapeutics
Names CEO

Emerging biopharmaceutical company Avila Therapeutics has appointed Katrine Bosley CEO as the company advances its business strategy, product pipeline, and proprietary platform of covalent drugs.

Ms. Bosley joins Avila from Adnexus where she most recently served as VP, strategic operations.

Dr. Pratik MULTANI

Fate Therapeutics Appoints Clinical
Development VP

Fate Therapeutics has appointed Pratik Multani, M.D., M.S., VP of clinical development.

In this role, Dr. Multani is responsible for leading Fate Therapeutics' upcoming clinical trials of stem cell modulators (SCMs).

Stem cell modulators are small molecules and biologics that guide cell fate for therapeutic purposes.

Stem cell modulators can potentially be applied in many areas, including regenerative medicine, hematological diseases, metastatic cancer, traumatic injury and degenerative diseases.

Before joining Fate Therapeutics, Dr. Multani was VP of translational medicine at Kalypsys.

Dr. Multani received an M.S. in clinical epidemiology from Harvard School of Public Health and an M.D. from Harvard Medical School.

Agency POOL

Mike BRUNE

Michael KOCH

Jim LOTHROP



Alyson ROMANELLI

Nicholas SANPHILIP

Anne SQUADRITO

Paul TRIOLO

Carbon Makes Promotions



Carbon, a CommonHealth professional advertising and promotion agency

serving the marketing needs of emerging pharmaceutical and specialty brands, has announced a number of promotions and one new hire.

Mike Brune, a CommonHealth veteran of 13 years, has been promoted to senior VP, creative director, copy.

Mr. Brune supervises his creative teams, ensuring all copy meets client expectations for quality and consistency.

Michael Koch has been promoted to account executive from assistant account executive.

He manages the daily responsibilities for their allocated accounts, guiding the successful implementation of brand marketing initiatives while maintaining client relations.

Jim Lothrop has advanced to group art supervisor from art supervisor.

Alyson Romanelli has been promoted to account group supervisor from account supervisor.

Nicholas SanPhilip has joined Carbon as a senior account executive. Mr. SanPhilip was previously senior account executive at The Harrington Group.

Anne Squadrito has been elevated to VP, group creative director, from her previous rank of VP, associate creative director.



TALENT pool

In this new role, Ms. Squadrito manages the creative teams and focuses on the cultivation of new business.



Paul Triolo has been promoted to account executive from assistant account executive.

He manages the daily responsibilities for his allocated accounts, guiding the successful implementation of brand marketing initiatives while maintaining client relations.

Mary **CHERUBINI**

Christina **DIBIASE**

Ed **O'BRIEN**

Mark **SOBRAY**

Publicis Selling Solutions Announces
New Hires

Publicis Selling Solutions, a leading provider of sales, service, and clinical teams for biopharma, has made a number of additions to its staff.

Publicis Selling Solutions is a Publicis Strategic Solutions Group company.

Mary Cherubini has been hired as client services director. Previously, Ms. Cherubini was manager, decision support systems, business operations, and analytics at Johnson & Johnson.

Christina DiBiase has been named national sales director, responsible for managing a new sales team for a leading pharmaceutical company client.

Ms. DiBiase was formerly director of sales at Johnson & Johnson Consumer Healthcare Products.

Ed O'Brien has joined Publicis Selling Solutions as director of human resources.

Mr. O'Brien was most recently director of human resources for Icon Clinical Research.

Mark Sobray has been appointed national business director for a new customer service team that is launching this year.

Mr. Sobray previously worked for Wyeth Consumer Healthcare as VP, medical sales & marketing.



Bethany (Beth) **HARTZELL**

Cadient Interactive Adds to Creative Team



Cadient Interactive, a Cadient Group company specializing in custom-created digital campaigns, tools, and services, has named Bethany (Beth) Hartzell associate creative director. Before joining Cadient Group, Ms. Hartzell was art director at Digitas Health.

Beth **JOY-DOUGHERTY**

CXHC Appoints New
Business Development Director

Connexion Healthcare (CXHC), a group of independent medical communications companies, has hired Beth Joy-Dougherty as director, new business development, with responsibility for further development and growth of CXHC, including its Clinical Connexion and Publication Connexion business units.

Ms. Joy-Dougherty has more than 16 years of pharmaceutical marketing and sales experience, and she most recently served as director of key account development for Poretta & Orr.

Ciro **MARIA**

MTI Expands Client Services Team

MTI, a provider of communication optimization solutions to healthcare providers, has appointed Ciro Maria executive director, client services. In this role, Mr. Maria is responsible for advancing key MTI client relationships.

Mr. Maria has more than 10 years of brand management and sales analysis experience in the healthcare industry, most recently as brand manager for GE Healthcare's computed tomography product line.

Andrew **MIELACH**

New Account Executive at Richard Lewis



Richard Lewis Communications, an independent investor relations and public relations firm, has named Andrew Mielach an account executive. Mr. Mielach was previously an account executive at Rx Mosaic Health.

Consulting **POOL**

Domenick **BERTELLI**

Putnam Associates Makes Promotion



Strategy consulting firm Putnam Associates has promoted Domenick Bertelli to partner. Mr. Bertelli joined Putnam Associates in 2003 and has advised pharmaceutical, biotech, and medical device clients on growth strategies, therapeutic area strategies, and pricing and reimbursement. He earned an MBA in new product and venture development from the MIT Sloan School of Management.

Lee **POTTS**

RPM Adds Project Director

Regulatory Presentation Management (RPM), a division of Presentation Strategies that helps medical, biotech, and pharmaceutical companies present to U.S. Food and Drug Administration advisory committees, has hired Lee Potts as a project director. Mr. Potts brings more than 16 years of tactical and logistical guidance as well as multimedia and graphic support to RPM. He most recently worked with Merck scientific/regulatory teams as they prepared for and presented at FDA advisory committee meetings.

Ed **SCHOONVELD**

ZS Associates Appoints Principal



Ed Schoonveld, a 20-year veteran of the pharmaceutical and consulting industries, has joined global consulting firm ZS Associates as principal and leader of the company's market access and pricing practice.

Mr. Schoonveld most recently served as VP of global pricing and reimbursement for Bristol-Myers Squibb. He received a master's degree in aeronautical engineering from Delft University of Technology in the Netherlands and an MBA in finance and international business from the Anderson School of Management at UCLA.

Gary **SULLIVAN**

MattsonJack Names VP



The Mattson Jack Group (MattsonJack), a Kantar Health company that provides business analytics and strategic decision support for the pharmaceutical and healthcare industries, has named Gary Sullivan VP.

Mr. Sullivan was most recently director of global market development for Procter & Gamble.

CRO **POOL**

Dr. Joseph

DEVEAUGH-GEISSDr. Michael **HAMRELL**Dr. William **MCCULLOCH**

Clinipace Appoints Advisory Team

Clinipace, a digital clinical research organization, has added three advisors to support the company's team of clinical development professionals, enabling Clinipace to enhance its existing clinical services while further deepening its therapeutic expertise.



Joseph DeVeugh-Geiss, M.D., has been named an advisor to the CNS, psychiatry, and internal medicine team.

Dr. DeVeugh-Geiss has more than 18 years of industry experience and has provided expert consultation to the pharmaceutical industry through his consulting company, Brainstorm CNS, since 2001.

Michael Hamrell, Ph.D., RAC, is advising the Clinipace regulatory team. Dr. Hamrell has more than 25 years of experience in regulatory affairs, clinical research, and product development.

He also serves as editor-in-chief of the Drug Information Journal and has received numerous awards for his research, teaching, and professional work.



William McCulloch, M.B., F.R.C.P., F.F.P.M., has been appointed advisor to the oncology and immunology team.

Over the past 25 years, Dr.

McCulloch has been a prolific researcher in the pharmaceutical industry who has contributed to more than a dozen IND and NDA submissions and more than two dozen scientific abstracts.

He also has published 14 peer-reviewed articles and has contributed three chapters to oncology-related treatment books.

Fredric **ESHELMAN**David **GRANGE**PPD Names
Chairman and CEO

Global contract research organization PPD has promoted Vice Chairman and CEO Fredric Eshelman to the newly created position of executive chairman.

In this role, Mr. Eshelman continues to be responsible for providing strategic direction to the company and overseeing the implementation of its strategic and business plans, including its compound partnering business.

Succeeding Mr. Eshelman as CEO is David Grange, a member of PPD's board since 2003.

In this new position, Mr. Grange is working closely with Mr. Eshelman to focus on key initiatives, strategic outsourcing plans, and core aspects of the company's operations.

Mr. Grange joins PPD after a decade of service to the McCormick Foundation, first as executive VP and chief operating officer, then as president and CEO since 2005.

He holds a master's degree in public service from Western Kentucky University.

Monte **JARVIS**Covance Appoints
Data Management VP

Covance has named Monte Jarvis VP of global data management and biostatistics for periapproval services.

In this position, Mr. Jarvis is responsible for overseeing data management and biostatistics for Phase IIIb/IV clinical studies, patient registries, and observational studies.

Mr. Jarvis was most recently VP, biometrics and global head of programming, for Icon.

He holds a master's degree in demography (actuarial statistics).

Kristie **LIVELY**Acorn CRO Strengthens
Management Team

Acorn CRO, an oncology-focused contract research organization, has added Kristie Lively, R.N., B.S.N., to its senior management team. As VP, Ms. Lively is responsible for overseeing all aspects of Acorn CRO's operations and services.

Ms. Lively has more than 15 years of healthcare industry experience with a strong background in quality assurance and operations.

She was most recently a VP for a large clinical research organization, conducting community-based clinical trials in oncology and other therapeutic areas.

Dr. Asli **MEMISOGLU**WWC Appoints
Data Management Director

Imaging CRO WorldCare Clinical (WCC) has named Asli Memisoglu, Ph.D., director of biostatistics and data management.

In this new position, Dr. Memisoglu oversees the development of image analysis performance metrics, statistical design, and database management between WCC's project managers, its sponsors, and independent reviewers.

Dr. Memisoglu previously served as associate director of biostatistics at Acusphere.

She received a master's degree in epidemiology and a doctorate in molecular science and cellular toxicology from Harvard University.

Laura **MIOLLA**NERI Adds Business
Development Director

New England Research Institutes (NERI), a privately held, full-service contract research organization, has appointed Laura Miolla as director of business development.

She serves as the primary client relationship manager responsible for identifying, developing, and expanding new business opportunities.

TALENT pool

Ms. Miolla's appointment is part of NERI's strategic business plan to enhance and grow its private-sector CRO client base.

Previously, Ms. Miolla served as director of business development for Clinsys Clinical Research. She holds an M.A. from Tufts University, where she graduated summa cum laude.

Caroline **TOLMAN-SALINAS**

SRI Names Director of
Sample Testing Laboratory



SRI International, an independent, nonprofit research and development organization, has appointed Caroline Tolman-Salinas director of Quality Clinical Labs (QCL), SRI's commercial clinical sample testing laboratory.

QCL specializes in clinical hematology and chemistry evaluations for pharmaceutical and medical device research applications and is the oldest established laboratory of its type in California performing clinical pathology analyses in full compliance with good laboratory practice (GLP) regulations.

Ms. Tolman-Salinas first joined SRI in February 2008 and has served as the acting director of QCL since May 2008.

In her new role, she is responsible for overall operations of the lab, including supervision of staff, technical oversight, and liaison with clients.

Dr. Scott **TREIBER**

inVentiv Clinical Promotes Head of
CRO Services Group



inVentiv Clinical Solutions, a division of inVentiv Health, has promoted Scott Treiber, Ph.D., to executive VP, clinical development solutions, from senior VP, clinical operations.

In this new role, Dr. Treiber is responsible for leading the contract research organization services (CROS) group and facilitating the interaction between clinical service groups.

He received a Ph.D. in biology from the University of California Santa Cruz and an MBA from Ellis College of New York Institute of Technology.

Dr. Hal **WARD**

Premier Research Selects
Pharmacovigilance Head

International pharmaceutical services company Premier Research Group has appointed Hal Ward, R.Ph., Pharm.D., as executive director, global pharmacovigilance.

Dr. Ward was most recently executive director and global head of drug safety at Covance's late-stage development services clinical division.

Media **POOL**

Dr. Ivan **ORANSKY**

Reuters Health Appoints
Executive Editor

Reuters Health, a unit of the Reuters news agency owned by Thomson Reuters, has named Ivan Oransky, M.D., executive editor.

In this role, Dr. Oransky heads the editorial operations of the global medical and health-care news service and drives its continued development as the industry's leading news source.

Dr. Oransky joins Reuters Health from Scientific American, where he was the online managing editor.

He is a board member of the Association of Health Care Journalists (AHCJ) and a member of the National Association of Science Writers.

Medical Education **POOL**

Ann Marie **DEMATTEO**

CME Names VP

CME LLC has named Ann Marie DeMatteo VP of educational initiatives.

In this new role, Ms. DeMatteo guides the development of educational programs that address unmet educational needs through activities founded on proven learning adult principles.

Ms. DeMatteo has more than 16 years of experience in the grant-development cycle, most recently as director of educational planning for Applied Clinical Education.

Service **POOL**

Eric **CARO**

Steve **LEONARD**

Catalent Pharma Solutions Adds Staff



Catalent Pharma Solutions, a provider of advanced technologies and outsourced services to the global pharmaceutical, biotechnology, and consumer health industries, has named Eric Caro product manager for the printed components business of its packaging services segment.

In this role, Mr. Caro's responsibilities include providing technical support to the plant and sales team on labels and inserts and driving new and existing projects through the organization to increase speed to market.

Before joining Catalent, Mr. Caro was a research and development manager and a senior account executive for Cortegra.



In other moves, Catalent has appointed Steve Leonard senior VP of global operations. Mr. Leonard joins Catalent after more than two decades at GE, where he most recently served as general manager of global operations for GE Healthcare's medical diagnostics business.

Peg **CONNELLY**

Randy **KEHRMEYER**

Kforce Clinical Research Announces
Executive Promotions

Kforce Clinical Research, a division of Kforce Inc. and provider of clinical trial resourcing solutions, has announced two promotions among its executive teams.



Peg Connelly has been promoted to VP of clinical operations, with responsibility for strategic leadership and operational excellence for pharmaceutical client alliances. Ms. Connelly has led the Kforce Pfizer Alliance for Site Management since joining Kforce in July 2007.



Kforce also has promoted Randy Kehmeyer to president from group VP of strategic customer partnerships. In this new

role, Mr. Kehrmeyer holds general management responsibilities for business strategy, business development, operations, strategic accounts, field operations, and P&L.

Dr. Michael CULLEN

MSL360° Appoints
Medical Chief



MSL360°, a full-service medical science liaison (MSL) and medical affairs company, has appointed Michael Cullen, M.D., chief medical officer in conjunction with the company's launch of the LEARN training program.

MSL360°'s LEARN program is designed to offer biopharmaceutical industry professionals, consultants, and investors the opportunity to quickly expand their knowledge of a specific therapeutic area through interactions with experienced medical practitioners.

As chief medical officer, Dr. Cullen is using his more than two decades of experience to contribute to curricula development, including content design and faculty selection for LEARN programs.

He received an M.D. from the University of Minnesota and an MBA from the University of St. Thomas in St. Paul, Minn.

Mark DEGATANO

Impact Rx Strengthens Business
Development Team



Mark Degatano has joined Impact Rx as VP, business development, key client initiatives.

In this newly created position, Mr. Degatano is leading programs designed to extend the value of Impact Rx's market intelligence offerings and is working to develop internal initiatives to ensure consistent delivery of these offerings across the company's entire customer base.

Before joining Impact Rx, Mr. Degatano served as principal of his own consulting firm following a career at Merck that spanned more than two decades.

Impact Rx provides market intelligence aimed at helping clients track the promotional initiatives of the pharmaceutical industry and measure their impact on physician prescribing behavior.

Ed EMDE

Tom ROTH

Wilson Learning Selects Head
of Americas Business

Wilson Learning Corporation, the U.S.-based business of Wilson Learning Worldwide, has named Ed Emde president. Tokyo-based Wilson Learning Worldwide is a global provider of human performance improvement solutions.

Mr. Emde brings 25 years of experience to this role. He is responsible for Wilson Learning's business in the Americas.

Mr. Emde succeeds Tom Roth, who has been appointed to the newly created position of president, global solutions group, for Wilson Learning Worldwide. Mr. Roth remains based at Wilson Learning Corporation's Edina, Minn., location.

Jeff FORRINGER

Rich GRAY

Steve HAMANN

Mike RAQUET

IntrinsicQ Appoints New Leadership Team

IntrinsicQ has named a new leadership team as part of its mission to improve the quality of cancer care by giving every stakeholder in the oncology field more clarity and insight into the clinical care process.

Jeff Forringer has been promoted to president after six years of successfully growing IntrinsicQ's pharmaceutical oncology consulting practice.



Rich Gray has joined IntrinsicQ as division general manager of the IntelliDose clinical software division.



Mr. Gray has more than 25 years of healthcare information technology experience to manage sales, marketing, product management, and customer satisfaction teams for IntrinsicQ.



Steve Hamann has been promoted to VP of technology following two years of spearheading a strategic roadmap to improve the user interface and underlying architecture of IntelliDose.



IntrinsicQ has appointed Mike Raquet division general manager of the pharmaceutical data division, spearheading pharmaceutical client service efforts to further the knowledge and understanding of oncology treatment.

Mr. Raquet has 25 years of pharmaceutical industry experience in clinical research, marketing, sales, and manufacturing and has held senior-level positions at IMS Health, PRA International, and Tunnell Consulting.

Technology POOL

Alan ARROYO

Nextrials Promotes Sales VP



Nextrials, a provider of clinical research software and services, has promoted Alan Arroyo to VP of global sales and marketing from his previous role as a senior director of business development.

With more than 12 years of clinical research and business development experience within the pharmaceutical industry, Mr. Arroyo's addition to the executive team enables the company to better leverage its leadership in the movement to deliver true integration of electronic data capture (EDC) technology with platforms used to create and manage electronic health records (EHR).

Philip PEAD

Eclipsys Names CEO

Eclipsys has named Philip Pead president and CEO, succeeding R. Andrew Eckert, who is leaving the company.

Mr. Pead, an Eclipsys director, was previously chairman, president, and CEO of Per-Se Technologies, which was acquired by McKesson in 2007.

Eclipsys is a provider of advanced integrated clinical; revenue cycle and performance management software; clinical content; and professional services that help healthcare organizations improve clinical, financial, and operational outcomes. ♦

Send your personnel announcements to
feedback@pharmavoice.com.



Building monster brands.

A monster brand doesn't just appear out of nowhere. Nor is it a figment of the imagination. It is built on a solid strategic foundation and nurtured with creative excellence. A monster brand has real presence in the market. It talks to its audience in a tone they want to hear—it inspires, motivates, moves the market. And it has the substance to endure.

S&H has plenty of experience creating monster brands. As one of the world's first healthcare agencies, we've been doing it longer than anyone.

If you'd like your brand to become the stuff of legend, contact:
Louisa Holland at 212-614-3838/louisa.holland@sudler.com
Rob Rogers at 212-614-4830/rob.rogers@sudler.com.

www.sudler.com



SUDLER & HENNESSEY

Find more inside your brand.